TY  - JOUR
AU  - Coles, Alasdair J
AU  - Jones, Joanne L
AU  - Vermersch, Patrick
AU  - Traboulsee, Anthony
AU  - Bass, Ann D
AU  - Boster, Aaron
AU  - Chan, Andrew
AU  - Comi, Giancarlo
AU  - Fernandez, Oscar
AU  - Giovannoni, Gavin
AU  - Kubala-Havrdova, Eva
AU  - LaGanke, Christopher
AU  - Montalban, Xavier
AU  - Oreja-Guevara, Celia
AU  - Piehl, Fredrik
AU  - Wiendl, Heinz
AU  - Ziemssen, Tjalf
PY  - 2021
DO  - 10.1177/13524585211061335
UR  - http://hdl.handle.net/10668/20223
T2  - Multiple sclerosis (Houndmills, Basingstoke, England)
AB  - Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab? In the extended phase 2/3 trials, 34/96 (35.4%) patients with and...
LA  - en
PB  - Sage Publications
KW  - Multiple sclerosis
KW  - Alemtuzumab
KW  - Autoimmunity
KW  - Post-marketing
KW  - Product surveillance
KW  - Risk assessment
KW  - Treatment outcome
KW  - Alemtuzumab
KW  - Autoimmunity
KW  - Clinical Trials, Phase II as Topic
KW  - Clinical Trials, Phase III as Topic
KW  - Humans
KW  - Marketing
KW  - Multiple Sclerosis
KW  - Multiple Sclerosis, Relapsing-Remitting
TI  - Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
TY  - research article
VL  - 28
ER  -